Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AAK1 | Q2M2I8 | 12/20 | 0.53 |
| ▸ | BRAF | P15056 | 5/20 | 0.40 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.40 |
| ▸ | CDK8 | P49336 | 1/20 | 0.40 |
| ▸ | CLK2 | P49760 | 1/20 | 0.40 |
| ▸ | CDK7 | P50613 | 1/20 | 0.40 |
| ▸ | CDK9 | P50750 | 1/20 | 0.40 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.40 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.40 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.40 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.40 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.40 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.40 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16974343 | 0.81 | AAK1 (0.49) | AAK1 | |
| SCHEMBL16974283 | 0.78 | BACE1 (0.42) | KDM4EALDH1A1 | |
| SCHEMBL27887117 | 0.73 | HSD17B1 (0.46) | MAP4K4LRRK2CLK4ALDH1A1 | |
| SCHEMBL20505858 | 0.73 | PIM1 (0.36) | KDM4ENPC1ALDH1A1TP53HPGD | |
| SCHEMBL16974140 | 0.73 | AAK1 (0.49) | AAK1BRAFMAP4K4CDK8CLK2 | |
| SCHEMBL16974306 | 0.72 | AAK1 (0.72) | AAK1 | |
| SCHEMBL16974141 | 0.71 | AAK1 (0.56) | AAK1 | |
| SCHEMBL1293407 | 0.70 | HSD17B1 (0.46) | MAP4K4LRRK2CLK4 | |
| SCHEMBL1293774 | 0.70 | GSK3B (0.50) | LRRK2KDM4E | |
| SCHEMBL28275841 | 0.69 | AAK1 (1.00) | AAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3099673-B1 | QUINOLINE-BASED KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2018-09-26 | — | — | EP | claimed |
| US-9932320-B2 | Quinoline-based kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-04-03 | — | — | US | claimed |
| EP-3099673-A1 | QUINOLINE-BASED KINASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2016-12-07 | — | — | EP | claimed |
| US-20160332985-A1 | Quinoline-Based Kinase Inhibitors | BRISTOL-MEYERS SQUIBB COMPANY (US) | 2016-11-17 | — | — | US | claimed |
| WO-2015116492-A1 | QUINOLINE-BASED KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-08-06 | — | — | WO | claimed |
| EP-3099673-B1 | QUINOLINE-BASED KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2018-09-26 | — | — | EP | disclosed |
| US-9932320-B2 | Quinoline-based kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-04-03 | — | — | US | disclosed |
| US-9932320-B2 | Quinoline-based kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-04-03 | — | — | US | disclosed |
| US-9932320-B2 | Quinoline-based kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-04-03 | — | — | US | disclosed |
| EP-3099673-A1 | QUINOLINE-BASED KINASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2016-12-07 | — | — | EP | disclosed |
| US-20160332985-A1 | Quinoline-Based Kinase Inhibitors | BRISTOL-MEYERS SQUIBB COMPANY (US) | 2016-11-17 | — | — | US | disclosed |
| US-20160332985-A1 | Quinoline-Based Kinase Inhibitors | BRISTOL-MEYERS SQUIBB COMPANY (US) | 2016-11-17 | — | — | US | disclosed |
| US-20160332985-A1 | Quinoline-Based Kinase Inhibitors | BRISTOL-MEYERS SQUIBB COMPANY (US) | 2016-11-17 | — | — | US | disclosed |
| WO-2015116492-A1 | QUINOLINE-BASED KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-08-06 | — | — | WO | disclosed |
| WO-2015116492-A1 | QUINOLINE-BASED KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-08-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160332985-A1 | Quinoline-Based Kinase Inhibitors | AAK1, EEF2K, ADCK1 | AAK1 1/4885BRAF 541/4885MAP4K4 203/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.